[ad_1]
Joel Saget (AFP / Scanpix) nuotr.
The COVID-19 vaccine, developed by the American biotech company Moderna, will primarily target the American market for many approaches and may not be available to poor countries, according to The Guardian.
The British publication recalls that the US administration has provided federal funding for the vaccine.
By the end of the year, the company plans to introduce 20 million in the US market. dose, says The Guardian.
Another important factor is the final price of this vaccine.
It is very expensive. In the summer, Moderna targeted $ 37 per dose, which is significantly more expensive for the uJohnson & Johnson ($ 10) or Pfizer ($ 20) vaccines, paymi’s post.
He predicts that in the case of large purchases, Moderna will likely agree to change prices.
But in any case, it is a mon for profit and has made it clear that it will be pursued, ”writes The Guardian.
Given the price of the vaccine and Moderna’s relationship with the US administration, the rest of the world will have to reward her, and countries with low per capita income will likely have to find an alternative, the article’s authors say.
The media said yesterday that the modern COVID-19 vaccine has a great advantage. For example, it is especially suitable for people over 65 and its side effects are mild and short-lived. In particular, in some cases, the test participants experienced hand pain and fatigue after the injection.
As of today, Moderna announced on Monday that its experimental vaccine against COVID-19 had shown an effectiveness of 94.5%. Also, depending on its collection, the vaccine can be stored for 2-8 months at room temperature.
In comparison, the Pfizer and BioNTech vaccine must be stored at minus 70-80 degrees at room temperature, which greatly complicates their logistics, and the poorest countries simply will not have the necessary equipment.
The reproduction of BNS information in the media and on websites without the consent of the UAB “BNS” is prohibited.
Rayti komentar
[ad_2]
